Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: Systematic review and meta-regression analysis

Matthias Briel, Ignacio Ferreira-Gonzalez, John J. You, Paul J. Karanicolas, Elie A. Akl, Ping Wu, Boris Blechacz, Dirk Bassler, Xinge Wei, Asheer Sharman, Irene Whitt, Suzana Alves Da Silva, Zahira Khalid, Alain J. Nordmann, Qi Zhou, Stephen D. Walter, Noah Vale, Neera Bhatnagar, Christopher O'Regan, Edward J. MillsHeiner C. Bucher, Victor Manuel Montori, Gordon H. Guyatt

Research output: Contribution to journalArticle

341 Citations (Scopus)

Abstract

Objective To investigate the association between treatment induced change in high density lipoprotein cholesterol and total death, coronary heart disease death, and coronary heart disease events (coronary heart disease death and non-fatal myocardial infarction) adjusted for changes in low density lipoprotein cholesterol and drug class in randomised trials of lipid modifyinginterventions. Design Systematic review and meta-regression analysis of randomised controlled trials. Data sources Medline, Embase, Central, CINAHL, and AMED to October 2006 supplemented by contact with experts in the field. Study selection In teams of two, reviewers independently determined eligibility of randomised trials thattested lipid modifying interventions to reduce cardiovascular risk, reported high density lipoprotein cholesterol and mortality or myocardial infarctions separately for treatment groups, and treated and followed participants for at least six months. Data extraction and synthesis Using standardised, pre- piloted forms, reviewers independently extracted relevant information from each article. The change in lipid concentrations for each trial and the weighted risk ratios for clinical outcomes were calculated. Results The meta-regression analysis included 108 randomised trials involving 299 310 participants at risk of cardiovascular events. All analyses that adjusted for changes in low density lipoprotein cholesterol showed no association between treatment induced change in high density lipoprotein cholesterol and risk ratios for coronary heart disease deaths, coronary heart disease events, or total deaths. With all trials included, change in high density lipoprotein cholesterol explained almost no variability (<1%) in any of the outcomes. The change in the quotient of low density lipoprotein cholesterol and high density lipoprotein cholesterol did not explain more of the variability in any of the outcomes than did the change in low density lipoprotein cholesterol alone. For a 10 mg/dl (0.26 mmol/1) reduction in low density lipoprotein cholesterol, the relative risk reduction was 7.2% (95% confidence interval 3.1% to 11%; P=0.001) for coronary heart disease deaths, 7.1% (4.5% to 9.8%; P<0.001) for coronary heart disease events, and 4.4% (1.6% to 7.2%; P=0.002) for total deaths, when adjusted for change in high density lipoprotein cholesterol and drug class. Conclusions Available data suggestthat simply increasing the amount of circulating high density lipoprotein cholesterol does not reduce the risk of coronary heart disease events, coronary heart disease deaths, or total deaths. The results support reduction in low density lipoprotein cholesterol as the primary goal for lipid modifying interventions.

Original languageEnglish (US)
JournalBMJ (Online)
Volume338
Issue number7693
DOIs
StatePublished - Feb 28 2009

Fingerprint

HDL Cholesterol
Coronary Disease
Meta-Analysis
Cardiovascular Diseases
Regression Analysis
Morbidity
LDL Cholesterol
Mortality
Lipids
Odds Ratio
Myocardial Infarction
Information Storage and Retrieval
Risk Reduction Behavior
Pharmaceutical Preparations
Randomized Controlled Trials
Confidence Intervals

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality : Systematic review and meta-regression analysis. / Briel, Matthias; Ferreira-Gonzalez, Ignacio; You, John J.; Karanicolas, Paul J.; Akl, Elie A.; Wu, Ping; Blechacz, Boris; Bassler, Dirk; Wei, Xinge; Sharman, Asheer; Whitt, Irene; Da Silva, Suzana Alves; Khalid, Zahira; Nordmann, Alain J.; Zhou, Qi; Walter, Stephen D.; Vale, Noah; Bhatnagar, Neera; O'Regan, Christopher; Mills, Edward J.; Bucher, Heiner C.; Montori, Victor Manuel; Guyatt, Gordon H.

In: BMJ (Online), Vol. 338, No. 7693, 28.02.2009.

Research output: Contribution to journalArticle

Briel, M, Ferreira-Gonzalez, I, You, JJ, Karanicolas, PJ, Akl, EA, Wu, P, Blechacz, B, Bassler, D, Wei, X, Sharman, A, Whitt, I, Da Silva, SA, Khalid, Z, Nordmann, AJ, Zhou, Q, Walter, SD, Vale, N, Bhatnagar, N, O'Regan, C, Mills, EJ, Bucher, HC, Montori, VM & Guyatt, GH 2009, 'Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: Systematic review and meta-regression analysis', BMJ (Online), vol. 338, no. 7693. https://doi.org/10.1136/bmj.b92
Briel, Matthias ; Ferreira-Gonzalez, Ignacio ; You, John J. ; Karanicolas, Paul J. ; Akl, Elie A. ; Wu, Ping ; Blechacz, Boris ; Bassler, Dirk ; Wei, Xinge ; Sharman, Asheer ; Whitt, Irene ; Da Silva, Suzana Alves ; Khalid, Zahira ; Nordmann, Alain J. ; Zhou, Qi ; Walter, Stephen D. ; Vale, Noah ; Bhatnagar, Neera ; O'Regan, Christopher ; Mills, Edward J. ; Bucher, Heiner C. ; Montori, Victor Manuel ; Guyatt, Gordon H. / Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality : Systematic review and meta-regression analysis. In: BMJ (Online). 2009 ; Vol. 338, No. 7693.
@article{50ce10974b27421eb57addfaba2a6739,
title = "Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: Systematic review and meta-regression analysis",
abstract = "Objective To investigate the association between treatment induced change in high density lipoprotein cholesterol and total death, coronary heart disease death, and coronary heart disease events (coronary heart disease death and non-fatal myocardial infarction) adjusted for changes in low density lipoprotein cholesterol and drug class in randomised trials of lipid modifyinginterventions. Design Systematic review and meta-regression analysis of randomised controlled trials. Data sources Medline, Embase, Central, CINAHL, and AMED to October 2006 supplemented by contact with experts in the field. Study selection In teams of two, reviewers independently determined eligibility of randomised trials thattested lipid modifying interventions to reduce cardiovascular risk, reported high density lipoprotein cholesterol and mortality or myocardial infarctions separately for treatment groups, and treated and followed participants for at least six months. Data extraction and synthesis Using standardised, pre- piloted forms, reviewers independently extracted relevant information from each article. The change in lipid concentrations for each trial and the weighted risk ratios for clinical outcomes were calculated. Results The meta-regression analysis included 108 randomised trials involving 299 310 participants at risk of cardiovascular events. All analyses that adjusted for changes in low density lipoprotein cholesterol showed no association between treatment induced change in high density lipoprotein cholesterol and risk ratios for coronary heart disease deaths, coronary heart disease events, or total deaths. With all trials included, change in high density lipoprotein cholesterol explained almost no variability (<1{\%}) in any of the outcomes. The change in the quotient of low density lipoprotein cholesterol and high density lipoprotein cholesterol did not explain more of the variability in any of the outcomes than did the change in low density lipoprotein cholesterol alone. For a 10 mg/dl (0.26 mmol/1) reduction in low density lipoprotein cholesterol, the relative risk reduction was 7.2{\%} (95{\%} confidence interval 3.1{\%} to 11{\%}; P=0.001) for coronary heart disease deaths, 7.1{\%} (4.5{\%} to 9.8{\%}; P<0.001) for coronary heart disease events, and 4.4{\%} (1.6{\%} to 7.2{\%}; P=0.002) for total deaths, when adjusted for change in high density lipoprotein cholesterol and drug class. Conclusions Available data suggestthat simply increasing the amount of circulating high density lipoprotein cholesterol does not reduce the risk of coronary heart disease events, coronary heart disease deaths, or total deaths. The results support reduction in low density lipoprotein cholesterol as the primary goal for lipid modifying interventions.",
author = "Matthias Briel and Ignacio Ferreira-Gonzalez and You, {John J.} and Karanicolas, {Paul J.} and Akl, {Elie A.} and Ping Wu and Boris Blechacz and Dirk Bassler and Xinge Wei and Asheer Sharman and Irene Whitt and {Da Silva}, {Suzana Alves} and Zahira Khalid and Nordmann, {Alain J.} and Qi Zhou and Walter, {Stephen D.} and Noah Vale and Neera Bhatnagar and Christopher O'Regan and Mills, {Edward J.} and Bucher, {Heiner C.} and Montori, {Victor Manuel} and Guyatt, {Gordon H.}",
year = "2009",
month = "2",
day = "28",
doi = "10.1136/bmj.b92",
language = "English (US)",
volume = "338",
journal = "The BMJ",
issn = "0959-8146",
publisher = "BMJ Publishing Group",
number = "7693",

}

TY - JOUR

T1 - Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality

T2 - Systematic review and meta-regression analysis

AU - Briel, Matthias

AU - Ferreira-Gonzalez, Ignacio

AU - You, John J.

AU - Karanicolas, Paul J.

AU - Akl, Elie A.

AU - Wu, Ping

AU - Blechacz, Boris

AU - Bassler, Dirk

AU - Wei, Xinge

AU - Sharman, Asheer

AU - Whitt, Irene

AU - Da Silva, Suzana Alves

AU - Khalid, Zahira

AU - Nordmann, Alain J.

AU - Zhou, Qi

AU - Walter, Stephen D.

AU - Vale, Noah

AU - Bhatnagar, Neera

AU - O'Regan, Christopher

AU - Mills, Edward J.

AU - Bucher, Heiner C.

AU - Montori, Victor Manuel

AU - Guyatt, Gordon H.

PY - 2009/2/28

Y1 - 2009/2/28

N2 - Objective To investigate the association between treatment induced change in high density lipoprotein cholesterol and total death, coronary heart disease death, and coronary heart disease events (coronary heart disease death and non-fatal myocardial infarction) adjusted for changes in low density lipoprotein cholesterol and drug class in randomised trials of lipid modifyinginterventions. Design Systematic review and meta-regression analysis of randomised controlled trials. Data sources Medline, Embase, Central, CINAHL, and AMED to October 2006 supplemented by contact with experts in the field. Study selection In teams of two, reviewers independently determined eligibility of randomised trials thattested lipid modifying interventions to reduce cardiovascular risk, reported high density lipoprotein cholesterol and mortality or myocardial infarctions separately for treatment groups, and treated and followed participants for at least six months. Data extraction and synthesis Using standardised, pre- piloted forms, reviewers independently extracted relevant information from each article. The change in lipid concentrations for each trial and the weighted risk ratios for clinical outcomes were calculated. Results The meta-regression analysis included 108 randomised trials involving 299 310 participants at risk of cardiovascular events. All analyses that adjusted for changes in low density lipoprotein cholesterol showed no association between treatment induced change in high density lipoprotein cholesterol and risk ratios for coronary heart disease deaths, coronary heart disease events, or total deaths. With all trials included, change in high density lipoprotein cholesterol explained almost no variability (<1%) in any of the outcomes. The change in the quotient of low density lipoprotein cholesterol and high density lipoprotein cholesterol did not explain more of the variability in any of the outcomes than did the change in low density lipoprotein cholesterol alone. For a 10 mg/dl (0.26 mmol/1) reduction in low density lipoprotein cholesterol, the relative risk reduction was 7.2% (95% confidence interval 3.1% to 11%; P=0.001) for coronary heart disease deaths, 7.1% (4.5% to 9.8%; P<0.001) for coronary heart disease events, and 4.4% (1.6% to 7.2%; P=0.002) for total deaths, when adjusted for change in high density lipoprotein cholesterol and drug class. Conclusions Available data suggestthat simply increasing the amount of circulating high density lipoprotein cholesterol does not reduce the risk of coronary heart disease events, coronary heart disease deaths, or total deaths. The results support reduction in low density lipoprotein cholesterol as the primary goal for lipid modifying interventions.

AB - Objective To investigate the association between treatment induced change in high density lipoprotein cholesterol and total death, coronary heart disease death, and coronary heart disease events (coronary heart disease death and non-fatal myocardial infarction) adjusted for changes in low density lipoprotein cholesterol and drug class in randomised trials of lipid modifyinginterventions. Design Systematic review and meta-regression analysis of randomised controlled trials. Data sources Medline, Embase, Central, CINAHL, and AMED to October 2006 supplemented by contact with experts in the field. Study selection In teams of two, reviewers independently determined eligibility of randomised trials thattested lipid modifying interventions to reduce cardiovascular risk, reported high density lipoprotein cholesterol and mortality or myocardial infarctions separately for treatment groups, and treated and followed participants for at least six months. Data extraction and synthesis Using standardised, pre- piloted forms, reviewers independently extracted relevant information from each article. The change in lipid concentrations for each trial and the weighted risk ratios for clinical outcomes were calculated. Results The meta-regression analysis included 108 randomised trials involving 299 310 participants at risk of cardiovascular events. All analyses that adjusted for changes in low density lipoprotein cholesterol showed no association between treatment induced change in high density lipoprotein cholesterol and risk ratios for coronary heart disease deaths, coronary heart disease events, or total deaths. With all trials included, change in high density lipoprotein cholesterol explained almost no variability (<1%) in any of the outcomes. The change in the quotient of low density lipoprotein cholesterol and high density lipoprotein cholesterol did not explain more of the variability in any of the outcomes than did the change in low density lipoprotein cholesterol alone. For a 10 mg/dl (0.26 mmol/1) reduction in low density lipoprotein cholesterol, the relative risk reduction was 7.2% (95% confidence interval 3.1% to 11%; P=0.001) for coronary heart disease deaths, 7.1% (4.5% to 9.8%; P<0.001) for coronary heart disease events, and 4.4% (1.6% to 7.2%; P=0.002) for total deaths, when adjusted for change in high density lipoprotein cholesterol and drug class. Conclusions Available data suggestthat simply increasing the amount of circulating high density lipoprotein cholesterol does not reduce the risk of coronary heart disease events, coronary heart disease deaths, or total deaths. The results support reduction in low density lipoprotein cholesterol as the primary goal for lipid modifying interventions.

UR - http://www.scopus.com/inward/record.url?scp=79953867783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953867783&partnerID=8YFLogxK

U2 - 10.1136/bmj.b92

DO - 10.1136/bmj.b92

M3 - Article

C2 - 19221140

AN - SCOPUS:79953867783

VL - 338

JO - The BMJ

JF - The BMJ

SN - 0959-8146

IS - 7693

ER -